| 영문 | virus | 한글 | 바이러스 |
|---|---|---|---|
| 설명 | 박테리아보다 덜 진화된, 생물과 무생물의 중간단계에 해당하는 것. 혼자서는 생존능력이 없으므로 반드시 다른 세포내에 속해 있어야 한다. 인체에 발생하는 많은 병중, 이 바이러스로 인해 발생하는 경우가 많으며, 이 때 대부분 특이한 치료법은 없는 실정이다. 일부 헤르페스바이러스 계통에는 치료약이 개발되어 있지만, 이것도 일부 질병에서만 치료가 가능하다. 또한, Ebstein-Barr virus, Human papilloma virus 등은 암의 발생과 연관되어 있으며, 동물에서 발생하는 대부분의 암종은 바이러스와 연관되어 있는 경우가 많다. 요즘, 일부 지역에서 큰 유행을 하고 있는 후천성면역결핍증후군(AIDS)도 HIV(Human Immunodeficiency Virus)와 관련이 있다. |
||
| 영문 | simian virus | 한글 | 원숭이바이러스 |
|---|---|---|---|
| 설명 | 원숭이에서 분리된 바이러스. 아데노바이러스, 엔테로바이러스, 헤르페스바이러스 및 레오바이러스 등의 여러 군에 속한다. |
||
| 영문 | influenza virus | 한글 | 인플루엔자바이러스 |
|---|---|---|---|
| 설명 | 인플루엔자의 병원체. 상기도 점막에 침입하여 호흡기 질환을 일으킨다. 보체 결합 항원의 차이에 따라 A-B-C 세형태로 나뉘며, 유행할 때마다 혈구 응집 항원이 변이하여 광범위한 유행을 나타낸다. 껍질이 있는 80~150nm의 공모양, 나선 대칭 RNA 바이러스이다. 두 종류의 스파이크, 뉴라미니다아제(neuraminidase, NA), 당단백질과 헤마글루티닌(hemagglution, HA) 당단백질을 만든다. A형의 NA에는 N1-N2의 두 종류, HA에는 HAO-HA1-HA2-HA3의 네 종류가 있다. A형은 말-돼지-새에 감염하며 새로운 아형은 동물 바이러스와의 조환형이며, 그 밖에 동일 아형내 점변이가 있다. B, C형은 사람 이외에는 감염되지 않는다. 닭의 적혈구를 응집하는 성질이 있다. 바이러스 진단에는 환자의 인두 세척액에서 분리한다든가, 또는 환자의 혈청항체에 의한 특이적 적혈구 응집저지검사, 뉴라미니다아제 활성저지검사 또는 중화검사 등으로 검출한다. |
||
| BPTI | basic pancreatic trypsin inhibitor; basic polyvalent trypsin inhibitor; bovine pancreatic trypsin in... |
|---|---|
| PI | first meiotic prophase; isoelectric point; pacing impulse; package insert; pancreatic insufficiency;... |
| IHA | idiopathic hyperaldosteronism; indirect hemagglutination; indirect hemagglutination antibody |
| HII | Health Industries Institute; Health Insurance Institute; hemagglutination inhibitor immunoassay |
| PHI | passive hemagglutination inhibition; past history of illness; phosphohexose isomerase; physiological... |
| HIT | Hemagglutination inhibition test |
|---|---|
| IAHA | Immune adherence hemagglutination |
| IHA | Indirect Hemagglutination assay |
| PHA | Passive hemagglutination assays |
| ACE inhibitor | angiotensin converting enzyme inhibitor |
| hemagglutination | <haematology> Agglutination of red blood cells, often used to test for the presence of antibodies directed against red cell surface antigens or carbohydrate binding proteins or viruses in a solution. Requires that the agglutinin has at least two binding sites. (18 Nov 1997) |
|---|---|
| a1-trypsin inhibitor | A glycoprotein that is the major protease inhibitor of human serum, is synthesised in the liver, and is genetically polymorphic due to the presence of over 20 alleles; individuals appropriately homozygous are deficient in a1-trypsin and are predisposed to pulmonary emphysema and juvenile hepatic cirrhosis because of alterations in the amino acid and sialic acid components of the glycoprotein. A1-Antitrypsin also inhibits thrombin. Synonym: a1-trypsin inhibitor, human a1-proteinase inhibitor. (05 Mar 2000) |
| ACE inhibitor | <pharmacology> A group of antihypertensive medications that work by inhibiting an enzyme (angiotensin-converting enzyme) that is important in the regulation of blood pressure. Studies have also indicated that it may help prevent or slow the progression of kidney disease in patients with diabetes. Examples include: captopril, ramipril, enalapril, losartan potassium, bepridil and lisinopril. (12 Mar 1998) |
| aldose reductase inhibitor | <pharmacology> A class of drugs being studied as a way to prevent eye and nerve damage in people with diabetes. Aldose reductase is an enzyme that is normally present in the eye and in many other parts of the body. It helps change glucose (sugar) into a sugar alcohol called sorbitol. Too much sorbitol trapped in eye and nerve cells can damage these cells, leading to retinopathy and neuropathy. Drugs that prevent or slow (inhibit) the action of aldose reductase are being studied as a way to prevent or delay these complications of diabetes. (09 Oct 1997) |
| angiotensin-converting enzyme inhibitor | <pharmacology> A class of drugs used in the treatment of hypertension and heart failure. They exert their haemodynamic effect mainly by inhibiting the renin-angiotensin system and produce a reduction of peripheral arterial resistance. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (14 Aug 2000) |
| aromatase inhibitor | Drugs, such as aminoglutethimide, that inhibit aromatase, an enzyme used in the synthesis of oestrogens. (05 Mar 2000) |
| beta-lactamase inhibitor | <pharmacology> Drugs such as clavulanic acid, which are used to inhibit bacterial beta-lactamases; often used with a penicillin or cephalosporin to overcome drug resistance. (05 Mar 2000) |
| Bowman-Birk inhibitor | A polypeptide that will inhibit both trypsin and chymotrypsin. (05 Mar 2000) |
| C1 esterase inhibitor | An a2-neuraminoglycoprotein that inhibits the enzymatic activity of C1 esterase, the activated first component of complement. A deficiency of this inhibitor results in a lack of inhibition of C1r and C1s leading to uncontrolled activation of the complement cascade and oedema. (05 Mar 2000) |
| carbonate dehydratase inhibitor | An agent, usually chemically related to the sulfonamides, that inhibits the activity of carbonate dehydratase, producing a general decrease in the formation of H2CO3 in the tissues. See: acetazolamide, dichlorphenamide. Synonym: carbonic anhydrase inhibitor. (05 Mar 2000) |
| carbonic acid inhibitor | <pharmacology> A group of diuretic medications which act to inhibit the enzyme carbonic anhydrase to create a metabolic acidosis. Many of these medications are used in the treatment of glaucoma. (27 Sep 1997) |
| carbonic anhydrase inhibitor | <pharmacology> A group of medications (sulphonamide drugs) which inhibit the enzyme carbonic anhydrase. These medications are used in the treatment of glaucoma. Examples include acetazolamide, dichlorphenamide and methazolamide. (27 Sep 1997) |
| mammary derived growth inhibitor | Fatty acid binding protein that inhibits proliferation of mammary carcinoma cells. (18 Nov 1997) |
| mechanism-based inhibitor | A competitive inhibitor that is converted to an irreversible inhibitor at the active site of the enzyme. Synonym: mechanism-based inhibitor. (05 Mar 2000) |
| glucosidase inhibitor | Agents such as acarbose which reduce gastrointestinal absorption of carbohydrates. This group of drugs has been known popularly as "starch blockers". They lower plasma glucose levels and tend to cause weight loss. A limiting side effect is flatulence. (05 Mar 2000) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|